These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2221856)

  • 1. Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment.
    Van der Auwera P; Stolear JC; George B; Dudley MN
    Antimicrob Agents Chemother; 1990 Aug; 34(8):1491-7. PubMed ID: 2221856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers.
    Jaehde U; Sörgel F; Naber KG; Zürcher J; Schunack W
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2092-7. PubMed ID: 8540722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.
    Marchbanks CR; Mikolich DJ; Mayer KH; Zinner SH; Dudley MN
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1966-72. PubMed ID: 2291662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin.
    Nix DE; Schultz RW; Frost RW; Sedman AJ; Thomas DJ; Kinkel AW; Schentag JJ
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():87-95. PubMed ID: 3162906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin.
    Misiak PM; Eldon MA; Toothaker RD; Sedman AJ
    J Clin Pharmacol; 1993 Jan; 33(1):53-6. PubMed ID: 8429114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency.
    Patel IH; Bornemann LD; Brocks VM; Fang LS; Tolkoff-Rubin NE; Rubin RH
    Antimicrob Agents Chemother; 1985 Jul; 28(1):46-50. PubMed ID: 4037777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of azlocillin in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Godin M; Fillastre JP
    Antimicrob Agents Chemother; 1980 Mar; 17(3):344-9. PubMed ID: 7425600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absorption and disposition of enoxacin in healthy subjects.
    Somogyi AA; Bochner F
    J Clin Pharmacol; 1988 Aug; 28(8):707-13. PubMed ID: 3216037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
    Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of enoxacin on renal and metabolic clearance of theophylline in rats.
    Nadai M; Hasegawa T; Kuzuya T; Muraoka I; Takagi K; Yoshizumi H
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1739-43. PubMed ID: 2285287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oral antacids on disposition of intravenous enoxacin.
    Nix DE; Lebsack ME; Chapelsky M; Sedman AJ; Busch J; Norman A
    Antimicrob Agents Chemother; 1993 Apr; 37(4):775-7. PubMed ID: 8494374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
    Flor S; Guay D; Opsahl J; Tack K; Matzke G
    Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
    Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
    Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA; Kohli RK; Harrison NJ; Schentag JJ
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
    Chang T; Black A; Dunky A; Wolf R; Sedman A; Latts J; Welling PG
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():49-56. PubMed ID: 3162901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of enoxacin in renal disease.
    Bury RW; Becker GJ; Kincaid-Smith PS; Moulds RF; Whitworth JA
    Clin Pharmacol Ther; 1987 Apr; 41(4):434-8. PubMed ID: 3470166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of moxalactam in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Fillastre JP
    Antimicrob Agents Chemother; 1981 Jun; 19(6):965-71. PubMed ID: 6455967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis.
    Francke EL; Appel GB; Neu HC
    Antimicrob Agents Chemother; 1979 Dec; 16(6):788-91. PubMed ID: 533260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
    Reitberg DP; Marble DA; Schultz RW; Whall TJ; Schentag JJ
    Antimicrob Agents Chemother; 1988 Apr; 32(4):503-9. PubMed ID: 3377461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.